Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults

The authors aimed to evaluate the efficacy and safety of an investigational mRNA-based seasonal influenza vaccine, mRNA-1010, in adults aged 50 and older. The phase 3 trial demonstrated that mRNA-1010 was superior to a standard-dose comparator vaccine in preventing RT-PCR-confirmed influenza-like illness, with a relative vaccine efficacy of 26.6%. While mRNA-1010 was associated with more frequent mild to moderate adverse reactions, serious adverse events were similar between the two groups.